天麻素联合多感官刺激对脑卒中后认知功能障碍患者的疗效分析

Efficacy of gastrodin combined with multisensory stimulation in patients with post-stroke cognitive impairment

  • 摘要:
    目的 观察天麻素联合多感官刺激对脑卒中后认知功能障碍患者神经功能及血清CXC趋化因子配体16(CXCL16)、血管内皮生长因子(VEGF)的影响。
    方法 选取2019年6月—2022年6月收治的130例脑卒中后认知功能障碍患者作为研究对象,将其分为单药组和联合组,每组65例。单药组给予天麻素治疗,联合组在单药组基础上联合多感官刺激疗法进行治疗。采用美国国立卫生研究院卒中量表(NIHSS)评分对神经功能进行评估; 采用简易精神状态量表(MMSE)和蒙特利尔认知评估量表(MOCA)评分评定认知功能; 采用酶联免疫吸附法(ELISA)检测血清CXCL16、VEGF水平。比较2组治疗总有效率及不良反应发生情况。
    结果 治疗后,联合组和单药组NIHSS评分均低于治疗前,且联合组NIHSS评分低于单药组,差异有统计学意义(P < 0.05)。治疗后,联合组和单药组MMSE评分和MOCA评分均高于治疗前,且联合组高于单药组,差异有统计学意义(P < 0.05)。治疗后,联合组和单药组血清CXCL16水平低于治疗前, VEGF水平高于治疗前,且联合组CXCL16水平低于单药组, VEGF水平高于单药组,差异有统计学意义(P < 0.05)。联合组治疗总有效率高于单药组,差异有统计学意义(P < 0.05)。
    结论 天麻素联合多感官刺激治疗可以降低患者血清CXCL16水平以及提高患者血清VEGF水平,改善脑卒中后认知功能障碍患者的神经功能。

     

    Abstract:
    Objective To observe the effects of gastrodin combined with multisensory stimulation on the neurological function and serum levels of CXC chemokine ligand 16 (CXCL16) and vascular endothelial growth factor (VEGF) in patients with post-stroke cognitive impairment.
    Methods A total of 130 patients with post-stroke cognitive impairment admitted from June 2019 to June 2022 were selected as study subjects and divided into monotherapy group and combination therapy group, with 65 patients in each group. The monotherapy group received gastrodin treatment, while the combination therapy group received both gastrodin and multisensory stimulation therapy. The National Institutes of Health Stroke Scale (NIHSS) was used to evaluate neurological function, the Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MOCA) scores were used to assess cognitive function, and enzyme-linked immunosorbent assay (ELISA) was used to detect serum levels of CXCL16 and VEGF. The total effective rate of treatment and the occurrence of adverse reactions were compared between the two groups.
    Results After treatment, both the monotherapy and combination therapy groups showed lower NIHSS scores than before treatment, with the combination therapy group showing lower NIHSS scores than the monotherapy group (P < 0.05). After treatment, both groups had higher MMSE and MOCA scores than before treatment, with the combination therapy group revealing higher scores than the monotherapy group (P < 0.05). Additionally, serum CXCL16 levels were lower and VEGF levels were higher in both groups after treatment compared to treatment before, with the combination therapy group showing lower CXCL16 levels and higher VEGF levels than the monotherapy group (P < 0.05). The total effective rate of treatment was higher in the combination therapy group than in the monotherapy group (P < 0.05).
    Conclusion Gastrodin combined with multisensory stimulation can reduce serum CXCL16 levels and increase serum VEGF levels in patients, thereby improving neurological function in patients with post-stroke cognitive impairment.

     

/

返回文章
返回